EEG Mapping and Low-Resolution Brain Electromagnetic Tomography (LORETA) in Diagnosis and Therapy of Psychiatric Disorders: Evidence for a Key-Lock Principle

Different psychiatric disorders, such as schizophrenia with predominantly positive and negative symptomatology, major depression, generalized anxiety disorder, agoraphobia, obsessive-compulsive disorder, multi-infarct dementia, senile dementia of the Alzheimer type and alcohol dependence, show EEG maps that differ statistically both from each other and from normal controls. Representative drugs of the main psychopharmacological classes, such as sedative and non-sedative neuroleptics and antidepressants, tranquilizers, hypnotics, psychostimulants and cognition-enhancing drugs, induce significant and typical changes to normal human brain function, which in many variables are opposite to the above-mentioned differences between psychiatric patients and normal controls. Thus, by considering these differences between psychotropic drugs and placebo in normal subjects, as well as between mental disorder patients and normal controls, it may be possible to choose the optimum drug for a specific patient according to a keylock principle, since the drug should normalize the deviant brain function. This is supported by 3–dimensional low-resolution brain electromagnetic tomography (LORETA), which identifies regions within the brain that are affected by psychiatric disorders and psychopharmacological substances.

[1]  Roberto D. Pascual-Marqui,et al.  Effect of the 5-HT1A partial agonist buspirone on regional brain electrical activity in man: a functional neuroimaging study using low-resolution electromagnetic tomography (LORETA) , 2000, Psychiatry Research: Neuroimaging.

[2]  T. Itil,et al.  EEG findings in chronic schizophrenics based on digital computer period analysis and analog power spectra. , 1972, Biological psychiatry.

[3]  F. Duffy,et al.  Significance probability mapping: an aid in the topographic analysis of brain electrical activity. , 1981, Electroencephalography and clinical neurophysiology.

[4]  M. Buchsbaum Handbook of Biological Psychiatry, Part II: Brain Mechanisms and Abnormal Behavior—Psychophysiology , 1981 .

[5]  H. Semlitsch,et al.  Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls. , 1996, Maturitas.

[6]  B. Saletu EEG Brain Mapping in Diagnostic and Therapeutic Assessment of Dementia , 1991, Alzheimer disease and associated disorders.

[7]  E. John,et al.  International Pharmaco-EEG group (IPEG). Recommendations for EEG and evoked potential mapping. , 1989, Neuropsychobiology.

[8]  P. Anderer,et al.  EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms Comparative studies with remoxipride/haloperidol , 1990, European Neuropsychopharmacology.

[9]  B Saletu,et al.  Topographic brain mapping of EEG in neuropsychopharmacology--Part I. Methodological aspects. , 1987, Methods and findings in experimental and clinical pharmacology.

[10]  T. Koenig,et al.  Low resolution brain electromagnetic tomography (LORETA) functional imaging in acute, neuroleptic-naive, first-episode, productive schizophrenia , 1999, Psychiatry Research: Neuroimaging.

[11]  E. John,et al.  Neurometrics: computer-assisted differential diagnosis of brain dysfunctions. , 1988, Science.

[12]  D. Lehmann,et al.  Low resolution electromagnetic tomography: a new method for localizing electrical activity in the brain. , 1994, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[13]  Bernd Saletu,et al.  Artifact processing in topographic mapping of electroencephalographie activity in neuropsychopharmacology , 1992, Psychiatry Research: Neuroimaging.

[14]  Thomas Dierks,et al.  Atlas of Brain Mapping: Topographic Mapping of Eeg and Evoked Potentials , 1991 .